Revenue Recognition (Tables)

9 Months Ended

Sep. 30, 2023

Revenue from Contract with Customer [Abstract]

Disaggregation of Revenue

Revenue is disaggregated by primary geographical market, major product line, and timing of revenue recognition.

In thousands	Three Months Ended September 30, 2023						Nine Months Ended September 30, 2023
Products By Geographic Area	Total		U.S.		Rest of World		Total		U.S.		Rest of World
Drug Revenues
Product Sales – Point-in-time	$	—	$	—	$	—	$	—	$	—	$	—
License Fee – Over time	2,197		—		2,197		2,327		—		2,327
Total Drug Products	2,197		—		2,197		2,327		—		2,327
Concentrates Products
Product Sales – Point-in-time	21,574		19,741		1,833		57,720		52,326		5,394
License Fee – Over time	—		—		—		1,472		1,472		—
Total Concentrate Products	21,574		19,741		1,833		59,192		53,798		5,394
Net Revenue	$	23,771	$	19,741	$	4,030	$	61,519	$	53,798	$	7,721

In thousands	Three Months Ended September 30, 2022						Nine Months Ended September 30, 2022
Products By Geographic Area	Total		U.S.		Rest of World		Total		U.S.		Rest of World
Drug Revenues
Product Sales – Point-in-time	$	193	$	193	$	—	$	834	$	561	$	273
License Fee – Over time	65		—		65		192		—		192
Total Drug Products	258		193		65		1,026		561		465
Concentrates Products
Product Sales – Point-in-time	17,953		16,619		1,334		51,035		46,334		4,701
License Fee – Over time	480		480		—		1,436		1,436		—
Total Concentrate Products	18,433		17,099		1,334		52,471		47,770		4,701
Net Revenue	$	18,691	$	17,292	$	1,399	$	53,497	$	48,331	$	5,166

Contract Balances

The following table provides information about receivables, contract assets, and contract liabilities from contracts with customers.

In thousands	September 30, 2023		December 31, 2022
Accounts Receivable, net	$	9,361	$	6,259
Contract Liabilities, which are included in deferred license revenue	$	533	$	4,331